<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01167062</url>
  </required_header>
  <id_info>
    <org_study_id>TAM040-0109</org_study_id>
    <nct_id>NCT01167062</nct_id>
  </id_info>
  <brief_title>Efficacy of Tamsulosin Oral-controlled Absorption System (OCAS) in the Treatment of Distal Ureteral Stones</brief_title>
  <official_title>Efficacy of Tamsulosin OCAS in the Conjunctive Medical Treatment of Distal Ureteral Stones.A Randomized, Double-blind, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ChaingMai University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ChaingMai University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized double blind placebo-controlled study that will assess the efficacy of
      Tamsulosin oral-controlled absorption system (OCAS) 0.4 mg in the conjunctive medical
      treatment of distal ureteral stones with a size of 4-10 mm compared to placebo in control
      group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  patient will be randomized to receive placebo or Tamsulosin OCAS 0.4 mg 1 tablet OD for
           a maximum of 28 days or until the ureteral stone is passed and sodium diclofenac 50 mg
           twice a day, for 10 days.

        -  All patients will receive 75 mg sodium diclofenac via intramuscular on demand
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <primary_completion_date type="Anticipated">April 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stone expulsion rate and time.</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of diclofenac injection used</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of occurrence of adverse events</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Ureteral Calculi</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamsulosin Hydrochloride OCAS 0.4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin Hydrochloride OCAS 0.4 mg</intervention_name>
    <description>One tablet OD for a maximum of 28 days</description>
    <arm_group_label>Tamsulosin Hydrochloride OCAS 0.4 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One tablet OD for a maximum of 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patient aged =&gt; 18 years.

          -  Patients who have distal ureteral stones with a size of 4-10 mm

          -  Written informed consent has been obtained.

        Exclusion Criteria:

          -  Patients with history of ureteral surgery

          -  Patients with urinary tract infection

          -  Patient with diabetes and peptic ulcer

          -  Patient with renal dysfunction (elevated of serum creatinine level)

          -  Patients with severe hydronephrosis

          -  Patients with history of passing stones

          -  Pregnancy

          -  Patients who desire to withdraw from the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bannakij Lojanapiwat, M.D.</last_name>
    <phone>66-53-945532</phone>
    <email>blojanap@mail.med.cmu.ac.th</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maharat Nakhon Chiangmai Hospital</name>
      <address>
        <city>Muang</city>
        <state>Chiangmai</state>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bannakij Lojanapiwat, M.D.</last_name>
      <phone>66-53-945532</phone>
      <email>blojanap@mail.med.cmu.ac.th</email>
    </contact>
    <investigator>
      <last_name>Bannakij Lojanapiwat, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2010</study_first_submitted>
  <study_first_submitted_qc>July 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2010</study_first_posted>
  <last_update_submitted>July 21, 2010</last_update_submitted>
  <last_update_submitted_qc>July 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Bannakij Lojanapiwat M.D</name_title>
    <organization>Chiang Mai University</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calculi</mesh_term>
    <mesh_term>Ureteral Calculi</mesh_term>
    <mesh_term>Ureterolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

